The Wasdell Group, an outsourced service provider to the life science sector, has expanded capabilities in its clinical division with significant investment in automated over-encapsulation equipment and randomization software. This investment is part of the group’s strategy to expand its clinical division and strengthens Wasdell’s capabilities at its Newcastle-Upon-Tyne facility.

“Tt is fantastic for us to be able to extend our capabilities in clinical activities to provide a fuller range of services to support customer trials,” said Ian Dufferwiel, general manager of Wasdell’s Newcastle site. “Demand is continuing to grow and we are very proud to be providing these services.”

The Wasdell Group recently communicated its decision to make its Newcastle facility the group’s center of excellence for clinical operations. During this announcement, CEO Vincent Dunne, said, “Our Newcastle facility will be the home of clinical operations for the Wasdell Group and we are excited to grow this division as well as the site. With its capabilities and experience in small batch manufacturing and packaging as well as the licenses and experience at site, we are confident of the foundation it presents to be able to build our clinical expansion on.”

From two sites in the UK and one in the EU, the Wasdell Group has become well-versed in managing manufacturing and packaging as well as the QP release and distribution of clinical material in the UK, EU, the U.S. and Japan. The company leverages the services offered at each of its sites to provide its clients with a holistic service for studies typically in phases 2 and 3.